High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 518-521

  Fizazi, K ^a   Chauveinc, L ^b   Prapotnich, D ^c   De Crevoisier, R ^a   Escudier, B ^a   Cathelineau, X ^c   Rozet, F ^c   Vallancien, G ^c   Sabatier, L ^b   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Circulating tumor cells; Prostate cancer; Telomerase

Indexed keywords

DIATRIZOATE; FICOLL; PROSTATE SPECIFIC ANTIGEN; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CELL ISOLATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; VOLUNTEER;

EID: 33847635749     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl419     Document Type: Article

References (30)

1. Loberg RD, Logothetis CJ, Keller ET et al. Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 2005; 23: 8232-8241.
2. Loberg RD, Fridman Y, Pienta BA et al. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia 2004, 6: 302-309.
3. Soria JC, Gauthier LR, Raymond E et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 971-975.
4. Latza U, Niedobitek G, Schwarting R et al. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990; 43: 213-219.
5. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 2034-2043.
6. Lin Y, Uemura H, Fujinami K et al. Telomerase activity in primary prostate cancer. J Urol 1997; 157: 1161-1165.
7. Zhang W, Kapusta LR, Slingerland JM et al. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998; 58: 619-621.
8. Gauthier LR, Granotier C, Soria JC et al. Detection of circulating carcinomas cells by telomerase activity. Br J Cancer 2001; 84: 631-635.
9. Soria JC, Morat L, Durdux C et al. The molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol 2002; 167: 352-356.
10. Grasso YZ, Gupta MK, Levin HS et al. Combined nested RT-PCR assay for prostate specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage. Cancer Res 1998; 58: 1456-1459.
11. Corey E, Arfman EW, Oswin MM et al. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997; 50: 184-188.
12. Chen BT, Loberg RD, Neeley CK et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005; 65: 616-621.
13. Pfitzenmaier J, Ellis WJ, Arfman EW et al. Telomerase activity in disseminated prostate cancer cells. BJU Int 2006; 97: 1309-1313.
14. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of an enhanced reverse-transcriptase-PCR assay. Urology 1994; 43: 765-775.
15. Israeli RS, Miller WH, Su SL et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostatic-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54: 6306-6310.
16. Seiden MV, Kantoff PW, Krithivas K et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1995; 12: 2634-2639.
17. Ghossein RA, Scher HI, Gerald WL et al. Detection of circulating tumour cells in patients with localised and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195-1200.
18. Sokoloff MH, Tso CL, Kaboo R et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: A clinicopathological molecular analysis of 121 patients. J Urol 1996; 156: 1560-1566.
19. Wood DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. J Clin Oncol 1997; 15: 3451-3457.
20. Hara N, Kasahara T, Kawasaki T et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one millilitre of peripheral blood. Clin Cancer Res 2002; 8: 1794-1799.
21. Zhang Y, Zippe CD, Van Lente F et al. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 1997; 3: 1215-1220.
22. de la Taille A, Olsson CA, Buttyan R et al. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term followup confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 1999; 84: 360-364.
23. Mejean A, Vona G, Nalpas B et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 2000; 163: 2022-2029.
24. Gewanter RM, Katz AE, Olsson CA et al. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology 2003; 61: 967-971.
25. Kantoff PW, Halabi S, Farmer DA et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 2001; 19: 3025-3028.
26. Halabi S, Small EJ, Hayes DF et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583. J Clin Oncol 2003; 21: 490-495.
27. Tombal B, Van Cangh PJ, Loric S et al. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003; 56: 163-170.
28. Ellis WJ, Pfitzenmaier J, Colli J et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003; 61: 277-281.
29. Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-718.
30. Ady N, Morat L, Fizazi K et al. Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 2004; 90: 443-448.